|
|
|
|
Welcome to MultiCASE Inc, the leading provider of artificial intelligence based bioactivity software, expert systems and in-silico consulting services for the Chemical and Pharmaceutical Industries
Our MissionWe develop and license computer programs designed to help the user to assess the potential adverse effects and metabolic properties of new chemicals both in virtual laboratory animals and in the environment. We also offer consulting services related to these issues as required for REACH submissions.
Company ProfileMultiCASE Inc. (formerly BIOSOFT Inc.) is a Software company started in Cleveland Ohio in 1996. The principal is Gilles Klopman, the Charles F. Mabery Professor of Chemistry at Case Western Reserve University (CWRU). Its business is to develop and license programs for use by chemical and pharmaceutical companies to design new useful molecules and to evaluate their impact on the environment at an early stage of development. The data for many of our expert systems have been developed by the US Food and Drug Administration ICSAS office and is used by many government regulatory agencies such as US, Canadian, Japan, Danish and the OECD in conjunction with the REACH program..
|
 | September 7, 2011 Please listen to the interview, given by Dr Klopman to Ashford Publishing |
| August 1st, 2011 CASE Ultra - version 1.4.0.0 a new generation of MultiCASE Inc products has been officially released. |
| July 27, 2011. MultiCASE Inc and Center for Drug Evaluation and Research of FDA have signed Research Cooperative Agreement “Enhancement of In Silico Decision Support Tools for the Evaluation of Drug Safety”. ( Details) |
| July 1st, 2011. MultiCASE Inc will be presentinga poster "Case Ultra: An Expert System for Computational Toxicology with a Novel Approach for Improving Risk Assessment of Chemicals " at Eurotox 2011 meeting in Paris (Aug 28-31st, 2011). please come and see us. |
| May 1st, 2011. Together with our collaborators from the US FDA Center for Drug Evaluation and Research, MultiCASE, Inc. presents “The Use of MultiCASE Software at FDA/CDER”, Room 2045 WO02, US FDA White Oak Campus, Silver Spring, MD, May 20, 2011. The FDA is pleased to sponsor this gathering of experts to discuss promising new scientific methodologies; however, the meeting should not be construed as an announcement of FDA guidance or regulations, or a FDA endorsement of MultiCASE, Inc. products. |
| January 29, 2011. Please come and visit us at our booth 666 during the ToxExpo 2011 in Washington DC. |
| January 28, 2011. MultiCASE Inc and Center for Food Safety and Applied Nutrition of FDA have signed Research Cooperative Agreement “Use of Collaborator’s Software to Develop Quantitative Structure-Activity Relationship (QSAR) Toxicity Models for CFSAN Regulatory Activities”. ( Details) |
| January 25-28, 2011. Web based user meetings have been held. Video recordings are available upon request. |
| January 15th, 2011. CASE Ultra - a new generation of MultiCASE Inc products has been unveiled. |
| We have acquired a certification in "Chemical Safety Assessment under REACH" and are offering consulting services for REACH submissions and dossier preparation. |
| We have acquired a new set of FDA ICSAS human adverse effect modules: Hepatobiliary, Renal and Urinary Tract and Cardiac Adverse Effects in Humans |
| MultiCASE inc has joined Insilico First, a unique collaborative endeavor, working to develop a pioneering computational prediction system to support the environmental safety assessment of chemicals. June 1st, 2008. |
|
Send mail to
saiakhov@multicase.com with
questions or comments about this web site.
|
Latest News